Aarti Drugs Limited (AARTIDRUGS.BO)
INR 330.65
(2.85%)
INR 330.65
(2.85%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 24.32 Billion INR | 0.45% |
| 2022 | 24.21 Billion INR | 9.67% |
| 2021 | 22.07 Billion INR | 25.02% |
| 2020 | 17.66 Billion INR | 12.02% |
| 2019 | 15.76 Billion INR | 7.77% |
| 2018 | 14.62 Billion INR | 5.4% |
| 2017 | 13.87 Billion INR | 17.88% |
| 2016 | 11.77 Billion INR | 6.82% |
| 2015 | 11.02 Billion INR | 10.01% |
| 2014 | 10.01 Billion INR | 17.91% |
| 2013 | 8.49 Billion INR | 18.07% |
| 2012 | 7.19 Billion INR | 17.48% |
| 2011 | 6.12 Billion INR | 17.03% |
| 2010 | 5.23 Billion INR | 24.91% |
| 2009 | 4.19 Billion INR | 3.93% |
| 2008 | 4.03 Billion INR | -3.22% |
| 2007 | 4.16 Billion INR | 13.74% |
| 2006 | 3.66 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 24.29 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 24.32 Billion INR | 0.0% |
| 2023 FY | 24.32 Billion INR | 0.45% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 23.51 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 22.68 Billion INR | 0.0% |
| 2022 FY | 24.21 Billion INR | 9.67% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 24.21 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 18.91 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 22.07 Billion INR | 0.0% |
| 2021 FY | 22.07 Billion INR | 25.02% |
| 2020 Q2 | 17.44 Billion INR | 0.0% |
| 2020 Q4 | 17.66 Billion INR | 0.0% |
| 2020 FY | 17.66 Billion INR | 12.02% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q4 | 15.76 Billion INR | 0.0% |
| 2019 Q2 | 15.09 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 15.76 Billion INR | 7.77% |
| 2018 Q4 | 14.62 Billion INR | 0.0% |
| 2018 Q2 | 14.41 Billion INR | 0.0% |
| 2018 FY | 14.62 Billion INR | 5.4% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q2 | 12.73 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 13.87 Billion INR | 17.88% |
| 2017 Q4 | 13.87 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 11.77 Billion INR | 6.82% |
| 2016 Q4 | 11.77 Billion INR | 0.0% |
| 2016 Q2 | 11.36 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q4 | 11.02 Billion INR | 0.0% |
| 2015 FY | 11.02 Billion INR | 10.01% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 11.26 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 9.23 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 10.01 Billion INR | 0.0% |
| 2014 FY | 10.01 Billion INR | 17.91% |
| 2013 FY | 8.49 Billion INR | 18.07% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 8.49 Billion INR | 0.0% |
| 2013 Q2 | 7.8 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q2 | 13 Billion INR | 0.0% |
| 2012 FY | 7.19 Billion INR | 17.48% |
| 2012 Q4 | 7.19 Billion INR | 0.0% |
| 2011 FY | 6.12 Billion INR | 17.03% |
| 2010 FY | 5.23 Billion INR | 24.91% |
| 2009 FY | 4.19 Billion INR | 3.93% |
| 2008 FY | 4.03 Billion INR | -3.22% |
| 2007 FY | 4.16 Billion INR | 13.74% |
| 2006 FY | 3.66 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 62.263% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 94.603% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 14.666% |
| Granules India Limited | 55.2 Billion INR | 55.943% |
| Indoco Remedies Limited | 21.44 Billion INR | -13.411% |
| Achyut Healthcare Limited | 309.52 Million INR | -7758.44% |
| Ajanta Pharma Limited | 46.38 Billion INR | 47.56% |
| Alkem Laboratories Limited | 155.74 Billion INR | 84.383% |
| Alpa Laboratories Limited | 1.82 Billion INR | -1231.912% |
| Brooks Laboratories Limited | 904.45 Million INR | -2589.313% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -125.63% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -217.902% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -100.381% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 93.723% |
| Eris Lifesciences Limited | 70.48 Billion INR | 65.493% |
| FDC Limited | 24.68 Billion INR | 1.448% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 83.06% |
| Gufic Biosciences Limited | 10.92 Billion INR | -122.633% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -108.767% |
| Ipca Laboratories Limited | 111.01 Billion INR | 78.089% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -1020.5% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -1265.155% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -1512.236% |
| Laurus Labs Limited | 83.87 Billion INR | 70.999% |
| Lupin Limited | 239.97 Billion INR | 89.864% |
| Mankind Pharma Limited | 119.63 Billion INR | 79.668% |
| Medicamen Biotech Limited | 2.94 Billion INR | -725.866% |
| Medico Remedies Limited | 961.95 Million INR | -2428.564% |
| Megasoft Limited | 3.65 Billion INR | -564.761% |
| NATCO Pharma Limited | 69.06 Billion INR | 64.781% |
| Piramal Pharma Limited | 153.11 Billion INR | 84.114% |
| RPG Life Sciences Limited | 5.12 Billion INR | -374.264% |
| Sigachi Industries Limited | 6.94 Billion INR | -250.405% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 97.154% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -7.909% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -501.082% |
| Unichem Laboratories Limited | 31.69 Billion INR | 23.254% |
| Wanbury Limited | 3.43 Billion INR | -608.125% |
| Windlas Biotech Limited | 6.26 Billion INR | -288.428% |
| ZIM Laboratories Limited | 4.46 Billion INR | -444.369% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 91.693% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -372.266% |
| Divi's Laboratories Limited | 154.7 Billion INR | 84.277% |
| Hester Biosciences Limited | 6.62 Billion INR | -267.233% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -206.204% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -563.002% |
| Bal Pharma Limited | 3.2 Billion INR | -659.19% |
| Strides Pharma Science Limited | 58.39 Billion INR | 58.348% |
| Venus Remedies Limited | 6.26 Billion INR | -288.041% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 5.799% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -11.013% |
| Shilpa Medicare Limited | 30.93 Billion INR | 21.364% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -8.375% |
| Suven Life Sciences Limited | 2.84 Billion INR | -753.751% |
| Ind-Swift Limited | 6.54 Billion INR | -271.653% |
| Valiant Laboratories Limited | 3.42 Billion INR | -609.79% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 39.102% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | -3.462% |
| Themis Medicare Limited | 5.66 Billion INR | -329.43% |
| Hikal Limited | 24.87 Billion INR | 2.203% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 83.85% |
| Sequent Scientific Limited | 15.4 Billion INR | -57.906% |
| Novartis India Limited | 9.24 Billion INR | -162.978% |
| Wockhardt Limited | 76.49 Billion INR | 68.2% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 78.938% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -5066.144% |
| Neuland Laboratories Limited | 18.32 Billion INR | -32.73% |
| Morepen Laboratories Limited | 12.93 Billion INR | -88.088% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -913.223% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -629.509% |